| Category | Subscription | Shares Offered | % of Total | Amount (₹Cr) |
|---|---|---|---|---|
|
Market Maker
|
Awaited |
138,000
|
— | ₹0.59 |
|
QIB
|
Over 76.99x
|
1,272,000
|
— | ₹5.47 |
|
NII / HNI
|
Over 1,664.45x
|
390,000
|
— | ₹1.68 |
|
Retail
|
Over 874.20x
|
900,000
|
— | ₹3.87 |
| Total | 598.69x | 2,562,000 |
100% | ₹11.02 |
| Category | Shares Offered | Amount (₹Cr) | Size (%) |
|---|---|---|---|
| QIB | 1,272,000 | ₹5.47 |
49.65%
|
| Market Maker | 138,000 | ₹0.59 |
5.39%
|
| NII | 390,000 | ₹1.68 |
15.22%
|
| Retail | 900,000 | ₹3.87 |
35.13%
|
| Total | 2,562,000 | ₹11.02 |
100.00%
|
| QIB | NII | Retail | Total | |||||
|---|---|---|---|---|---|---|---|---|
| Ex. Anchor | Anchor | Total QIB | Below ₹10L | Above ₹10L | Total NII | |||
| Allocation (shares) | — | — | — | — | — | 390,000 | 900,000 | 1,290,000 |
| Allotment price (₹) | 43 | 43 | 43 | 43 | 43 | 43 | 43 | 43 |
| No. of applications | — | — | — | — | — | — | — | — |
| No. of shares applied | — | — | — | — | — | — | — | — |
| Amount collected (₹Cr) | — | — | — | — | — | — | ₹3.87 | ₹3.87 |
| Times subscribed | 76.99x | — | — | — | — | 1,664.45x | 874.20x | 598.69x |
| Shares allotted | — | — | — | — | — | 390,000 | 900,000 | 1,290,000 |
| No. of allottees | — | — | — | — | — | — | — | — |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min — 2 Lots) | 2 | 6,000 | ₹258,000 |
| Retail (Max — 13 Lots) | 13 | 39,000 | ₹1,677,000 |
| S-HNI (Min — 14 Lots) | 14 | 42,000 | ₹1,806,000 |
| B-HNI (Min — 68 Lots) | 68 | 204,000 | ₹8,772,000 |
| Particulars | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Revenue from Operations | 28.06 | 23.57 | 19.85 |
| EBITDA | 5.83 | 4.30 | 2.19 |
| Profit After Tax (PAT) | 2.83 | 1.81 | 0.26 |
| Net Worth | 10.35 | 7.87 | 5.89 |
| Total Assets | 26.28 | 22.93 | 19.39 |
| Reserves & Surplus | 1.65 | 3.76 | 2.08 |
| Borrowings | 11.03 | 11.13 | 10.83 |
| EBITDA Margin (%) | 20.79 | — | — |
| PAT Margin (%) | 10.10 | — | — |
Goldline Pharmaceutical Ltd. IPO is subscribed 598.69 times by May 14, 2026. Retail: 874.20x. QIB: 76.99x. NII: 1,664.45x.
| Investor Category | Subscription |
|---|---|
| Qualified Institutional (QIB) | 76.99x |
| Non Institutional (NII/HNI) | 1,664.45x |
| Retail Individual | 874.20x |
| Total Subscription | 598.69x |
The Goldline Pharmaceutical Ltd. IPO retail category is subscribed 874.20 times as of 14 May 2026. The retail portion is oversubscribed.
Subscribe via your broker app using ASBA or UPI. Opens 12 May 2026 and closes 14 May 2026. Min investment: ₹129,000 (1 lot = 3,000 shares). UPI mandate: 5:00 PM on 14 May 2026.
The Goldline Pharmaceutical Ltd. IPO subscribed 598.69x overall. QIB: 76.99x, NII: 1,664.45x, Retail: 874.20x. Applications: from NSE/BSE.
Check allotment on the registrar website (Bigshare Services Pvt.Ltd) at https://ipo.bigshareonline.com/IPO_Status.html. Enter your PAN, application number or DP/Client ID. Allotment date: 15 May 2026. Refunds: on 18 May 2026.
The Goldline Pharmaceutical Ltd. IPO listing date is 19 May 2026, Tuesday. Listed on: BSE SME. Issue price: ₹43. Estimated listing: ₹69. GMP: +₹26.
The Goldline Pharmaceutical Ltd. IPO closes on 14 May 2026, Thursday. UPI mandate: 5:00 PM on 14 May 2026. Allotment: 15 May 2026. Listing: 19 May 2026.